Insulet CorporationPODDEarnings & Financial Report
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
PODD Q4 2025 Key Financial Metrics
营收
$783.7M
毛利润
$568.6M
营业利润
$146.2M
净利润
$101.6M
毛利率
72.6%
营业利润率
18.7%
净利率
13.0%
同比增长
31.2%
EPS
$1.42
资金流向
Insulet Corporation Q4 2025 Financial Summary
Insulet Corporation reported revenue of $783.7M for Q4 2025, with a net profit of $101.6M (13.0% margin). Cost of goods sold was $215.1M, operating expenses totaled $422.4M.
Key Financial Metrics
| Total Revenue | $783.7M |
|---|---|
| Net Profit | $101.6M |
| Gross Margin | 72.6% |
| Operating Margin | 18.7% |
| Report Period | Q4 2025 |
Insulet Corporation Annual Revenue by Year
Insulet Corporation annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.7B).
| Year | Annual Revenue |
|---|---|
| 2025 | $2.7B |
| 2024 | $2.1B |
| 2023 | $1.7B |
| 2022 | $1.1B |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $441.7M | $488.5M | $543.9M | $597.5M | $569.0M | $649.1M | $706.3M | $783.7M |
| 同比增长 | 69.0% | 23.2% | 25.7% | -1.5% | 28.8% | 32.9% | 29.9% | 31.2% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $2.62B | $2.88B | $3.03B | $3.09B | $3.52B | $3.47B | $3.03B | $3.19B |
| 总负债 | $1.83B | $1.88B | $1.91B | $1.88B | $2.19B | $2.01B | $1.65B | $1.68B |
| 股东权益 | $790.7M | $998.4M | $1.12B | $1.21B | $1.33B | $1.46B | $1.38B | $1.52B |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $87.6M | $96.5M | $98.5M | $147.7M | $63.8M | $196.5M | $125.7M | $183.3M |
Other Health Care Companies
ABT
Abbott Laboratories
营收
$11.4B
净利润
$1.6B
BAX
Baxter International
营收
$3.0B
净利润
$-1.1B
BDX
Becton Dickinson
营收
$5.3B
净利润
$382.0M
BSX
Boston Scientific
营收
$5.3B
净利润
$670.0M
DXCM
Dexcom
营收
$1.3B
净利润
$267.3M
EW
Edwards Lifesciences
营收
$1.6B
净利润
$291.1M
GEHC
GE HealthCare
营收
$5.7B
净利润
$588.0M
HOLX
Hologic
营收
$1.0B
净利润
$179.1M
IDXX
Idexx Laboratories
营收
$1.1B
净利润
$274.6M
ISRG
Intuitive Surgical
营收
$2.9B
净利润
$794.8M